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Abstract
Background:  Poly(ADP-ribosyl)ation is a posttranslational modification of nuclear proteins
catalysed by poly(ADP-ribose) polymerases (PARPs), using NAD+ as a substrate. Activation of
PARP-1 is in immediate response to DNA damage generated by endogenous and exogenous
damaging agents. It has been implicated in several crucial cellular processes including DNA repair
and maintenance of genomic stability, which are both intimately linked with the ageing process. The
measurement of cellular poly(ADP-ribosyl)ation capacity, defined as the amount of poly(ADP-
ribose) produced under maximal stimulation, is therefore relevant for research on ageing, as well
as for a variety of other scientific questions.
Results: This paper reports a new, robust protocol for the measurement of cellular poly(ADP-
ribosyl)ation capacity in PBMC or Jurkat T-cells using flow cytometry, based on a previously
established immuno-dot-blot assay. In order to validate the new assay, we determined the dose-
response curve of 3-aminobenzamide, a well-known competitive PARP inhibitor, and we derived
an IC50 that is very close to the published value. When testing a set of PBMC samples taken from
fifteen healthy young human donors, we could confirm the presence of a substantial interindividual
variation, as previously observed using a radiometric assay.
Conclusion:  The methodology described in this paper should be generally useful for the
determination of cellular poly(ADP-ribosyl)ation capacity in a wide variety of settings, especially for
the comparison of large sets of samples, such as population studies. In contrast to previously
published radiometric or immuno-dot-blot assays, the new FACS-based method allows (i) selective
analysis of mononuclear cells by gating and (ii) detection of a possible heterogeneity in poly(ADP-
ribosyl)ation capacity between cells of the same type.
Background
Ageing is a multifactorial degenerative process that affects
all tissues including the immune system [1]. There is evi-
dence for a loss of genomic stability in cells during normal
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ageing (for review: [2,3]). This genomic instability may
well be mediated by limitations in DNA repair pathways.
This view is supported by recent reports highlighting the
pivotal role of DNA repair (e.g. nucleotide excision repair)
in determining the rate of ageing [4], while on the other
hand proteins that are found deficient in syndromes of
accelerated ageing, such as the Werner protein (WRN),
have been shown to possess functions in DNA repair and
maintenance of genomic stability (for review: [2]).
The bioavailability and intracellular distribution of zinc
ions may well have an impact on processes related with
DNA repair and maintenance of genomic stability, and
thus on the ageing process [5]. This is apparent from the
fact that several DNA repair-related proteins are zinc-fin-
ger proteins [6]. One prominent example of a zinc finger
protein involved in DNA repair and genomic stability is
poly(ADP-ribose) polymerase-1 (PARP-1, EC 2.4.2.30).
PARP-1 catalyses one of the immediate cellular responses
to genotoxic stress, i.e. the synthesis of poly(ADP-ribose)
[3,7-10]. On the one hand, this enzyme is a very promis-
ing target for cancer chemotherapy [11], and especially so
for BRCA2-deficient tumour cells [12]. On the other hand,
an involvement of poly(ADP-ribose) metabolism in the
ageing process has long been suggested, as we could show
that the cellular capacity to produce poly(ADP-ribose) in
peripheral blood mononuclear cells (PBMC) correlates
positively with species-specific life span in mammals [13].
Furthermore, we were able to establish an association
between high cellular poly(ADP-ribosyl)ation capacity in
lymphoblastoid cells with human longevity [14].
Environmental toxins that can interfere with the structural
integrity of zinc fingers, such as arsenicals, have recently
been shown to suppress DNA damage-induced poly(ADP-
ribose) formation in living cells in culture, even at remark-
ably low concentrations that prevail in drinking water
from some geographical regions of the world [15]. Other
conditions that might lead to similar effects are oxidative
protein damage or diminished bioavailability of zinc,
resulting from either nutritional zinc deficiency or
changes in zinc transport or intracellular storage.
One of the tasks of the ZINCAGE project [5] supported by
the EU Commission is, therefore, to assess poly(ADP-
ribosyl)ation capacity in human PBMC as a function of
age and nutritional zinc status of the donor. The data
obtained will be correlated with series of other genetic,
biochemical and psychological parameters to be assessed
within ZINCAGE. Based on the importance and multi-
functional nature of poly(ADP-ribosyl)ation, it is obvious
that reliable and convenient methods to assess cellular
poly(ADP-ribosyl)ation capacities are needed.
Previously, various methods have been developed to
assess the cellular poly(ADP-ribosyl)ation capacity. This
was primarily achieved by incubating permeabilised cells
with a double-stranded activator DNA oligonucleotide
and then subsequently measuring the incorporation of
radiolabelled NAD+  into acid-insoluble material
[13,14,16]. There were, however, major drawbacks with
that methodology including the requirement of using
radioactivity, of relatively large cell numbers, and the
notorious inefficiency of the washing steps to remove any
unincorporated radioactively labelled NAD+ from trichlo-
roacetic acid (TCA) precipitates. Therefore, we subse-
quently developed a non-radioactive immuno-dot-blot
assay to quantify cellular poly(ADP-ribosyl)ation capacity
[17]. That method allowed permeabilised cells that had
been incubated with an activator oligonucleotide and
non-labelled NAD+ to be directly dot-blotted onto a nylon
membrane, and then TCA-precipitated in situ. Immuno-
detection of the resultant poly(ADP-ribose) was achieved
using a monoclonal antibody conjugated with a peroxi-
dase-based quantitative chemiluminescence detection
system. That method, however, did not allow separation
of specific cell types or detection of heterogeneity between
cells of the same type.
In the present paper we describe a new methodology
using a flow cytometry-based technique.
Results and discussion
In this study, a modification to an existing dot-blot assay
for the quantification of cellular poly(ADP-ribosyl)ation
capacity [17] was developed based on flow cytometry.
In order to assess levels of cellular poly(ADP-ribosyl)ation
by such a method, background levels of mean fluores-
cence intensity (MFI) had to be established. Initial exper-
iments were carried out using Protocol A to determine
MFI levels in untreated Jurkat T cells, i.e. cells with no anti-
body labelling, serving as a negative control and regarded
as a measure for background fluorescence. In addition,
antibody staining was performed on permeabilised cells
incubated with or without NAD+  in the presence or
absence of activator oligonucleotide. Figure 1 shows the
typical frequency distributions (histograms) obtained
with Protocol A. Figure 1(A) represents the negative con-
trol (MFI = 58.07), and can be regarded as background
fluorescence level as these cells were not antibody-
labelled. Panels (B) – (D) show the histograms of Jurkat T
cell samples stained with primary and secondary antibod-
ies after treatment of the cells as detailed in the protocol,
except for the lack of both NAD+ and the activator oligo-
nucleotide (B), or the lack of NAD+ only (C), or the lack
of oligonucleotide only (D). In panels B – D a slight
increase in MFI is apparent, ranging between approxi-
mately 130 and 180 units, reflecting more or less the back-Immunity & Ageing 2006, 3:8 http://www.immunityageing.com/content/3/1/8
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ground staining of the primary and secondary antibody,
as no significant amounts of poly(ADP-ribose) were pro-
duced under these conditions. Permeabilised cells, how-
ever, that had been incubated with NAD+ plus activator
oligonucleotide and stained with antibodies (Panel E)
yielded a severalfold higher fluorescence intensity (MFI =
793.41), as expected, because PARP-1 was fully stimulated
under these conditions. This result clearly indicates the
usefulness of flow cytometry as tool for assessment of
poly(ADP-ribosyl)ation capacity.
In the course of our experiments we developed a modified
assay protocol (Protocol B), for measuring PBMC. The
main differences between Protocol A and Protocol B are
(i) fixation/permeabilisation ("prefixation ") with 100%
ethanol before the reaction is started, and (ii) a second fix-
ation step using formaldehyde to be performed after the
PARP-1 reaction has taken place. The prefixation is done
to "stabilise" the cells for subsequent steps of the experi-
mental procedure. It should be noted that DNA strand
break-driven poly(ADP-ribosyl)ation occurs mainly as an
automodification of PARP-1 [18]. Polymer formation
leads to a strongly negatively charged protein modifica-
tion. This can lead to a repulsion effect as DNA is also neg-
atively charged, and therefore automodified PARP-1
might be lost from chromatin. Therefore a second fixation
step was introduced using formaldehyde. This modified
assay turned out to be more stable and reproducible and
is therefore the recommended assay format.
Flow cytometry provides the option of selecting certain
cell populations by gating. For example, we are interested
in measuring PARP activity specifically in PBMC and
therefore wish to exclude other cell types (such as plate-
lets) contaminating the preparation. PBMC can be stained
with a CD 45 antibody and selected by gating as is
depicted in Figure 2. This cell population was selectively
analysed in all subsequent experiments.
As is depicted in Figure 3, MFI values of human PBMC
incubated in the absence of NAD+ were very low, whereas
addition of NAD+ and, even more so, further addition of
activator oligonucleotide raised MFI by over tenfold. To
illustrate the usefulness of the flow cytometry-based assay
according to Protocol B, the well-known PARP inhibitor
3-aminobenzamide was added to the reaction mixture at
varying concentrations, i.e. 1, 3, 10, 30, 100, 300, and
1,000 μM (Fig. 3). As expected, a significant and concen-
tration-dependent inhibition of poly(ADP-ribose) forma-
tion was observed at concentrations between 30 and
1,000 μM, down to background levels at the highest con-
centration tested, thus demonstrating the specificity of the
immunostaining for poly(ADP-ribose). No significant
change was seen at 3-aminobenzamide concentration up
to 10 μM. The potency of the inhibitor observed in these
experiments corresponds very well with its known IC50 in
vitro (approximately 40 μM; [19]).
In previous work using a radiometric PARP activity assay
[13], we had observed significant interindividual hetero-
geneity between samples taken from young healthy
donors. This was the case for PBMC taken from any of the
mammalian species tested. At least to some extent that
heterogeneity may have been due to technical problems
related with inefficient removal of non-incorporated radi-
oactive NAD+. We therefore tested a set of PBMC samples
taken from fifteen healthy human donors (24–29 years of
age) using the new assay format (Table 1a). The average
activity level (i.e., [MFI with NAD+ and oligonucleotide] –
[MFI without NAD+] was 665 with a standard deviation of
419. These data reveal a substantial (several-fold) interin-
dividual variation, with no obvious gender difference. We
also observed such variability between donors tested in
parallel (Table 1a, donors marked with asterisks). This,
however, was not due to instability of the assay, as meas-
urements of PBMC from a single donor performed either
in parallel or in consecutive experiments on different days
displayed only marginal variability (Table 1b). Thus the
variability seen in Table 1a seems to be biological rather
than technical. Nevertheless, for large studies it is advisa-
ble to use internal standards like aliquots of cryopreserved
PBMC from a single donor. It will be interesting to deci-
pher the reasons for the pronounced interindividual vari-
ation as well as the possible biological consequences for
the individual. One candidate, on which we are focussing
in the ZINCAGE project, is the cellular zinc status.
Conclusion
The methodology described in this paper should be gen-
erally useful for the determination of cellular poly(ADP-
ribosyl)ation capacity in a wide variety of settings, espe-
cially for the comparison of large sets of samples, such as
population studies. In contrast to previously published
radiometric or immuno-dot-blot assays, the new FACS-
based method allows (i) selective analysis of mononu-
clear cells by gating and (ii) detection of a possible heter-
ogeneity in poly(ADP-ribosyl)ation capacity between cells
of the same type.
Methods
Materials
Phosphate Buffered Saline (Dulbecco A; PBS) was from
Oxoid, Basingstoke, UK. Foetal calf serum (FCS) was from
Invitrogen, Paisley, UK. Tris hydrochloride (Tris-HCl),
ethylenediaminetetraacetic acid (EDTA), magnesium
chloride (MgCl2), 2-mercaptoethanol, digitonin, β-nicoti-
namide adenine dinucleotide (NAD+; grade V), 3-ami-
nobenzamide (3-AB), sodium azide were from Sigma,
Poole, UK. The PARP activator deoxyoligonucleotide
(GGAATTCC) [16] was dissolved in 15 mM NaCl at 385Immunity & Ageing 2006, 3:8 http://www.immunityageing.com/content/3/1/8
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Frequency distributions (histograms) of MFI representing poly(ADP-ribosyl)ation levels in permeabilised Jurkat cells Figure 1
Frequency distributions (histograms) of MFI representing poly(ADP-ribosyl)ation levels in permeabilised Jur-
kat cells. (A) Untreated cells, no antibodies (Ab) added (negative control); (B) no NAD+ and no oligo in the reaction buffer; 
primary Ab, secondary Ab; (C) no NAD+, but oligo in the reaction buffer; primary Ab, secondary Ab; (D) NAD+, but no oligo 
in the reaction buffer; primary Ab, secondary Ab; (E) NAD+ and oligo in the reaction buffer; primary Ab, secondary Ab. Note 
that a shift to the right (FL-1; x-axis) indicates increased levels of poly(ADP-ribosyl)ation. Numerical values next to the histo-
grams represent the mean fluorescence intensity (MFI). M1, intensity range used to determine mean of FL1-H.Immunity & Ageing 2006, 3:8 http://www.immunityageing.com/content/3/1/8
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μg/ml. Percoll was from Amersham Bioscience, Uppsala,
Sweden. Mouse monoclonal antibody recognising
poly(ADP-ribose) was purified as described previously,
from culture supernatant of 10 H hybridoma cells [20]
(kind gift of M. Miwa and T. Sugimura, Tokyo, Japan)
using a protein-A column chromatography kit [17]. Alexa
Fluor®488 goat anti-mouse secondary antibody was from
Molecular Probes, Paisley, UK. CD 45 antibody was from
BD Bioscience, Erembodegem, Belgium.
Cells
Jurkat T cells, a leukaemic T cell line, were maintained as
a suspension culture in RPMI 1640 medium (Sigma) sup-
plemented with 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 2 mM L-glutamine and 10 % foetal calf serum
(Sigma). Cultures were incubated at 37°C and 5 % CO2.
Freshly obtained human PBMC from healthy donors were
isolated by Percoll gradient centrifugation [13].
FACS-based PARP-activity assay – Protocol A
To perform PARP activity assays, a modification of the dot
blot method according to Pfeiffer et al. [17] was used.
Jurkat T cells were counted, washed in PBS, pelleted and
resuspended in ice-cold hypotonic permeabilisation
buffer (10 mM Tris-HCl pH 7.8, 1 mM EDTA, 4 mM
MgCl2, 30 mM 2-mercaptoethanol) supplemented with
0.015% (w/v) digitonin (Sigma), and left on ice for 1
minute. A further 4 ml of digitonin-free, ice-cold permea-
bilisation buffer was then added and the cells were pel-
leted at 326 g, 4°C, for 10 minutes and resuspended again
in ice-cold permeabilisation buffer at a density of 2 × 105
cells/53 μl in a V-bottomed 96-well plate.
In order to investigate cellular poly(ADP-ribosyl)ation
capacity, the permeabilised Jurkat T cells were incubated
with activator oligonucleotide and non-labelled NAD+,
which acts as substrate, to allow formation of poly(ADP-
ribose).
Thirty-four μl of reaction buffer (100 mM Tris-HCl pH
7.8, 1 mM NAD+, 120 mM MgCl2) and 13 μl of double-
stranded activator oligonucleotide dissolved in 15 mM
NaCl at 385 μg/ml was added to samples of 2 × 105 cells
on ice, yielding a total volume of 100 μl per reaction. The
mixture was incubated at 37°C for 4 minutes, and then
cells were pelleted at 652 g, 4°C, for 3 minutes and resus-
pended in 60 μl PBS. The reaction was stopped by adding
140 μl of ice-cold 70% ethanol and incubation for 15
minutes at -20°C. Then cells were pelleted at 652 g, 4°C,
for 5 minutes and then washed in 240 μl of FACS buffer
(1 × PBS, 0.5% FCS, 2 mM NaN3), with shaking at 4°C,
and again centrifuged at 652 g, 4°C for 2 minutes.
The cell pellet was resuspended in 240 μl diluted primary
antibody (purified 10 H mouse monoclonal antibody rec-
ognising poly [ADP-ribose]; dilution 1:300 in FACS
buffer) at 4°C overnight. Cells were then pelleted at 652
g, 4°C, for 2 minutes and washed in 240 μl of FACS
buffer, as before. The resultant cell pellet was resuspended
in 240 μl Alexa 488-conjugated secondary antibody (dilu-
tion 1:1000 in FACS buffer; Invitrogen) in the dark fol-
lowed by shaking at room temperature for 30 minutes,
Separation of leukocytes by CD 45 staining and gating Figure 2
Separation of leukocytes by CD 45 staining and gating. (A) Gating of cells and classification as populations R1 and R2. 
(B) PBMC were stained with CD 45 antibody. The R1 population is CD 45-positive.
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Stimulation of PARP activity in permeabilised human PBMC by addition of NAD and activator oligonucleotide, and inhibitory  effect of 3-aminobenzamide Figure 3
Stimulation of PARP activity in permeabilised human PBMC by addition of NAD and activator oligonucle-
otide, and inhibitory effect of 3-aminobenzamide. A. Histograms of poly(ADP-ribosyl)ation levels determined using Pro-
tocol B. Permeabilised cells were incubated with NAD+ and activator oligonucleotide in the presence of the PARP inhibitor 3-
aminobenzamide as indicated. A representative set of data is shown. bckgr, background; ab, antibody; 3-AB, 3-aminobenzamide. 
Note that a shift to the right (FL-1; x-axis) indicates increased levels of poly(ADP-ribosyl)ation and that addition of PARP inhib-
itor 3-aminobenzamide reverses this shift. B. Quantitative evaluation of MFI. Shown are average values and SD of three parallel 
determinations, respectively, comprising the data set shown in A
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pelleted and washed once more and finally resuspended
in 240 μl FACS buffer and left on ice prior to flow cytom-
etry analysis.
Cell samples were analysed by flow cytometry in a FACS
Calibur II (Becton Dickinson Immunocytometry Systems)
operating with CellQuest version 3.3 software. The total
population of viable cells was gated to their forward and
side scatter. Control samples were evaluated in each
experiment. The fluorescence of untreated cells was
recorded to determine the level of background fluores-
cence for negative control cells, while treated cells with
primary and secondary antibody staining were used as
positive control cells. A total of 10,000 event files for each
sample were acquired individually in "live-gate" mode.
Data are expressed as mean fluorescence intensity (MFI)
above background.
FACS-based PARP-activity assay – Protocol B
This method is similar to Protocol A, except for the follow-
ing modifications: Ethanol, rather than digitonin, is used
for permeabilisation; the reaction time (incubation with
NAD+ and activator oligonucleotide) was extended to 10
min and this was followed by a second fixation using for-
maldehyde. For convenience this protocol (which is the
recommended version, see Discussion) is described here
in a step-by-step fashion:
￿ Centrifuge cells (2 × 105 per data point) in 15 ml tube
for 5 min at 326 g (note that about 1.5 × 106 PBMC can be
recovered from 1 ml of blood)
￿ Resuspend the pellet in 10 ml PBS
￿ Count the cells
Table 1b: Robustness of poly(ADP-ribosyl)ation capacity 
measurements of PBMC from one donor done either in parallel 
or consecutive assays.
parallel measurements MFI
220
190
165
269
210
197
Average 208
SD 35
consecutive measurements MFI
193
201
323
Average 239
SD 73
Cellular poly(ADP-ribosyl)ation capacity was measured using 
Protocol B. Top: Six independent reactions were started with PBMC 
from one donor within a single experiment. Bottom: The poly(ADP-
ribosyl)ation capacity of one donor was measured in PBMC from 
blood samples obtained on different days. Note the relatively small 
variability of the measurements in contrast to samples from different 
donors. MFI, mean fluorescence intensity; SD, standard deviation.
Table 1a: Heterogeneity of poly(ADP-ribosyl)ation capacity of PBMC from healthy young human donors.
Donor # Age Gender MFI
1* 29 m 601
2 29 m 410
3 28 m 914
4 28 m 546
5 27 m 283
62 6m 1 4 6 7
7 26 m 292
8* 29 f 1664
9* 29 f 462
10 29 f 433
11 28 f 793
12 27 f 838
13 27 f 553
14* 27 f 512
15 24 f 211
Average 665
SD 419
Cellular poly(ADP-ribosyl)ation capacity in PBMC of 15 young and healthy donors was measured using Protocol B. Note the high level of variability 
between donors. High variability was also noticed in a subset of samples processed in parallel in the same experiment (asterisks), with an average of 
809 and SD of 572. MFI, mean fluorescence intensity; SD, standard deviation.Immunity & Ageing 2006, 3:8 http://www.immunityageing.com/content/3/1/8
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￿ Centrifuge the cells for 5 min at 326 g
￿ Resuspend pellet in 100% ethanol (ice-cold)
￿ Leave at -20°C for at least 20 min
￿ Centrifuge the cells for 10 min at 815 g
￿ Resuspend the cell pellet in ~ 10 ml buffer A (10 mM
Tris-HCl pH 7.8, 1 mM EDTA, 4 mM MgCl2, 30 mM 2-
mercaptoethanol)
￿ Centrifuge the cells for 10 min at 815 g
￿ Resuspend pellet in N × 27 μl buffer A (N = number of
wells to be filled, each comprising 2 × 105 cells) and trans-
fer 27 μl per well into a V-shaped 96-well plate
￿ Incubate the plate with the cells on ice for at least 5 min
￿ Add 20 μl 3× reaction buffer (with or without NAD+)
plus 13 μl of 15 mM NaCl incorporating or not activator
oligonucleotide (final concentration: 5 μg per reaction)
thus reaching a final volume of 60 μl
￿ Leave at 37°C for 10 min
￿ Second fixation:
 Add 60 μl of 4% formaldehyde in PBS and incubate
for at least 20 min at room temperature
 add 60 μl of 100 mM glycine in PBS to quench for-
maldehyde
￿ Centrifuge for 10 min at 815 g
￿ Wash with 200 μl FACS buffer
￿ Centrifuge for 5 min at 815 g
￿ Resuspend the pellet in 100 μl primary antibody (10 H)
diluted in FACS buffer (final concentration 5 μg/ml)
￿ Incubate for 1 h at 37°C or overnight at 4°C
￿ Centrifuge for 5 min at 815 g
￿ Wash twice (as before)
￿ Centrifuge for 5 min at 815 g
￿ Resuspend pellet in 100 μl of diluted secondary anti-
body (Alexa 488-conjugated goat anti-mouse, dilution
1:1,000 in FACS buffer) N.B. This and the subsequent
steps should be done under subdued light.
￿ Incubate for 30 min at 37°C
￿ Wash twice (as before)
￿ Centrifuge for 5 min at 815 g
￿ Resuspend the pellet in 200 μl FACS buffer
￿ Leave on ice until FACS analysis (as described above) or
store the samples at 4°C
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